GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aelis Farma SA (XPAR:AELIS) » Definitions » Net Income From Continuing Operations

Aelis Farma (XPAR:AELIS) Net Income From Continuing Operations : €-5.08 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Aelis Farma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Aelis Farma's net income from continuing operations for the six months ended in Dec. 2023 was €-3.45 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was €-5.08 Mil.

Aelis Farma Net Income From Continuing Operations Historical Data

The historical data trend for Aelis Farma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aelis Farma Net Income From Continuing Operations Chart

Aelis Farma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial -3.17 -2.09 0.57 -14.29 -5.08

Aelis Farma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.21 -10.35 -3.94 -1.63 -3.45

Aelis Farma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-5.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aelis Farma (XPAR:AELIS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aelis Farma SA (XPAR:AELIS) » Definitions » Net Income From Continuing Operations
Comparable Companies
XPAR:IPH XPAR:IVA XPAR:MEDCL XPAR:GNFT XPAR:TNG XPAR:DBV XPAR:NANO XPAR:ADOC XPAR:ALSEN XPAR:OSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
69O:Germany
Address
146, rue Leo Saignat, Bordeaux, FRA, 33077
Website
https://www.aelisfarma.com
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases.

Aelis Farma (XPAR:AELIS) Headlines

No Headlines